In a continuation of a developing trend, two big-pharma executives left their cozy corner offices for the fast and wild biotech world. This year we have already seen a number of big names defect for the biotech world, the reasons for which were covered here. These latest appointments add further evidence to the fact that biotech has regained its form and now has pulling power.
Albireo Limited, a privately held company focused through its operating subsidiary on the development of bile acid modulators to treat orphan paediatric and adult liver diseases, NASH, and gastrointestinal disorders, appointed Ron Cooper has joined the company as President and Chief Executive Officer. Mr. Cooper is a global biopharmaceutical leader with a track record of growing businesses, brands and organizations in the U.S. and Europe. He joins Albireo from Bristol-Myers Squibb (BMS), where he was President of Europe. In addition, Albireo has established a U.S. subsidiary office in Boston, Massachusetts. The Chairman of the company is Dr. David Chiswell who also Chairman of Kymab, currently searching a new CEO after parting company with Christian Groendahl., who is now working with Bicycle Therapeutics Chairman, Andy Sandham at Syncona.
And it is Bicycle Therapeutics who have just hired Kevin Lee as CEO from Pfizer, where he was CSO of the Rare Diseases unit. Andrew Sandham, said: “Kevin is an accomplished leader with a proven track record developing novel biopharmaceuticals and business collaborations across therapeutic areas. His experience in translating emerging science into innovative drugs will be invaluable as we apply our product platform to create a pipeline of new therapeutics in oncology and other therapeutic areas.”